Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2020

View Archived Issues

Oligodendrocyte-neural connections not just about myelin

Sharper look yields new potential kinase target in ovarian cancer

DOTATATE uptake is higher in mCRPC patients with neuroendocrine transformation

Circulating ANGPTL8 as a marker of metabolic disorders in PCOS

Results from phase Ib portion of the CARTITUDE-1 study

Pandion begins first-in-human trial of PT-101 for autoimmune disease

Preclinical data presented for scAAV9/CLN7 gene replacement therapy

Trinucleotide expansions are too much of a good thing

Optimization and in vivo testing of bumetanide derivatives for temporal lobe epilepsy

Aclaris Therapeutics patents ITK and JAK3 inhibitors

Study of CoV-OC43 dissemination in mouse CNS and drug testing using non-invasive bioluminiscence

Structure-based screening unveils new melatonin receptor ligands that modulate circadian rhythms

Sitari Pharma divulges TGM2 inhibitors

Defibrotide safe in young patients with sickle cell disease undergoing stem cell transplantation

Inorbit Therapeutics AB synthesizes new NR1H4 agonists

University of Texas System identifies new PTPN11 inhibitors

Incyte patents MAP4K1 inhibitors

Tradipitant demonstrates antipruritic effect in mild atopic dermatitis in phase III EPIONE study

ProMIS announces pilot longitudinal study to assess blood-based biomarkers for Alzheimer's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...